Semler Scientific : November 2022 Presentation 2.1 MB

NASDAQ:SMLR

November 2022

Forward-Looking Statements

This presentation includes statements that are, or may be deemed, "forward-looking statements." In some cases, these forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believe," "estimate," "anticipate," "expect," "plan," "intend," "may," "could," "might," "will," "should," or, in each case, their negative or other variations thereon or comparable terminology, although not all forward-looking statements contain these words. Such forward-looking statements appear in a number of places throughout this presentation and include express and implied statements regarding QuantaFlo® aiding in diagnosis of other cardiovascular diseases, our up to $20.0 million buyback program and any purchases thereunder, new products and service offerings, our expected range of revenues and operating expenses for the fourth and full year of 2022, as well as our plans for maximizing stockholder returns and our goals for the year, among others. These statements are based on our current intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the impact of healthcare reform (including the Affordable Care Act) on our business, the effect of new financial incentives for medical providers and the amount of such payments, our ongoing and planned development of products, the timing of launch of such new products, the strength and breadth of our intellectual property, the degree of clinical utility and adoption of our product, particularly for specific patient populations, and the success of new service models.

By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics, our expected financing needs and sources of financing, the industry in which we operate and the trends that may affect the industry or us. Our results of operations, financial condition, liquidity, prospects, growth and strategies depend on the economic circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated. Although we believe that we have a reasonable basis for each forward-looking statement contained in this presentation, we caution you that forward- looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this presentation as a result of, among other factors, the factors referenced in the "Risk Factors" section of our Annual Report on Form 10-K as filed with the Securities and Exchange Commission on March 4, 2022 and as may be amended from time to time and the continued effects of the on-goingCOVID-19 pandemic, including our assumptions regarding its duration and the impact on use of our products and services and the recent seasonality observed in our variable (fee per test) and other geopolitical events that may impact our supply chain, such as the Russian invasion of Ukraine and inflation. In addition, even if our results of operations, financial condition and liquidity, and the development of the industry in which we operate are consistent with the forward-looking statements contained in this presentation, they may not be predictive of results of developments in future periods. Any forward-looking statements that we make in this presentation speak only as of the date of such statement, and we undertake no obligation to update such statements to reflect events or circumstances after the date of this presentation, except as required by law.

You should read carefully our "Cautionary Note Regarding Forward-Looking Statements and Industry Data" and the factors described in the "Risk Factors" sections of the Annual Report to better understand the risks and uncertainties inherent in our business.

2

Disruptive, Paradigm-shifting Business with Large Opportunity

Technology to bring Peripheral Arterial Disease (PAD) and cardiovascular testing to the front lines of medicine

High-leverage distribution model to Health Insurance Plans, Health Risk Assessment (HRAs) companies, and other emerging customers

Software as a service (SAAS) recurring-revenuesubscription licensing model

Large and underpenetrated addressable market opportunity

3

Investment Highlights

(in millions of U.S. Dollars)

Solid track record of growth and profitability

• Recurring SAAS revenue model
• Strong cash position of $45.5 million as of 9/30/22

• Income tax benefit of $4.4M primarily due to release of tax valuation allowance
• Covid-19impacted annual results

		2018				2019*				2020**				2021**
	$32.8	$38.6	$53.0
	$21.5			$5.3	$10.7	$16.0		$19.5	$5.0	$15.1	$14.0	$17.2
		R E V E N U E S				INCOME F ROM		NET INCOME
								OPERA TIONS

4

Solutions to Improve Healthcare for Age 50 and Over

Software and Products Platform

• Faster
• More practical to use
• More accurate
• Less expensive

5